Email Updates

You are here

Home

AVAC's Blog: P-Values

  • New START Data Fill in When to Start ART, Now the Question is How

    New data from a trial looking at the individual health benefits of starting those living with HIV on antiretroviral therapy (ART) at CD4 cell counts above 350 were released today. The data, from a trial known as START, are further evidence in support of the expansion of ART access worldwide. The data from START should also start the clock on even more substantial engagement with the types of ART programs that are most likely to help people make informed choices to begin and remain on life-saving treatment.

    May 27, 2015
    Treatment
    AVAC

  • Clearinghouse on Male Circumcision for HIV Prevention Redesigned

    FHI 360 in collaboration with WHO, UNAIDS and AVAC have announced the upgrade of the Clearinghouse on Male Circumcision for HIV Prevention website — a collaborative effort between these organisations. The new design comes with enhanced form and functionality that will ensure more user-friendly navigation, a modern look, an enhanced search function, an interactive map and a new resources library among other things.

    May 22, 2015
    Voluntary Medical Male Circumcision
    AVAC

  • Africa, Why?

    South African advocate and 2014 AVAC Fellow, Yvette Raphael, who is master trainer at the Center for Communications Impact (formerly JHHESA), shares a personal story of her insights on the xenophobic attacks in South Africa and the acts of violence, abuse and terrorism that have recently happened in different parts of Africa. She challenges everyone to think differently, more effectively, and strategically about these developments in this powerful, personal and passionate blog, and highlights implications of these and similar events to HIV research, service delivery and way of life.

    May 21, 2015
    Yvette Raphael

  • Choosing the Worst Time to Scale Back AIDS Research

    A vaccine isn’t just needed, it’s also very possible. Just this year, researchers launched studies that could lead to the first vaccine licensed for use. While it won’t be the perfect vaccine, it could make a real difference if proven to be even partially effective. The future path of science is never clear. But we can be certain that slowing down now would be a huge mistake – for American scientific leadership, and for millions of people whose lives depend on it.

    May 18, 2015
    HIV Vaccine
    Mitchell Warren

  • Researcher reveals decision-making criteria for possible AIDS vaccine efficacy trials in 2017

    A vaccine candidate will only move to large-scale efficacy trials – which are the prerequisite for licensure – if researchers decide it has a good chance for success. How will they know, and when will they know it?
    May 18, 2015
    HIV Vaccine
    AVAC

  • HIV Vaccine Development Process has Come a Long Way

    Ugandan advocate, Sylvia Nakasi joined the rest of the world to commemorate HIV Vaccine Awareness Day on May 18 by thoughtful opinion piece in the New Vision. In her piece, Sylvia highlights how far HIV vaccine research and devlopment has come and calls for the need for continued investments in the search for an effective HIV vaccine. Sylvia also underscores the need to ensure that the options that are currently available – including treatment, voluntary counseling and testing, voluntary medical male circumcision, male and female condoms, pre-exposure prophylaxis (PrEP) etc – reach the people who need them the most. Sylvia is a Policy and Advocacy Officer at Uganda Network of AIDS Service Organisations (UNASO) and was an AVAC Advocacy Fellow in 2011.
    May 16, 2015
    HIV Vaccine
    Sylvia Nakasi

  • Why We're Hopeful this HIV Vaccine Awareness Day

    On May 18, advocates around the world observe HVAD—an annual commemoration of the need for and commitment to the ongoing search for a vaccine. Download slides and audio from our HVAD webinar—Vaccines in Vivo: AIDS vaccine clinical trials in 2015—and click here for our updated HVAD Toolkit and check out what advocates are saying.
    May 13, 2015
    HIV Vaccine
    AVAC

  • Webinar: Why We're Hopeful this HIV Vaccine Awareness Day

    On Monday, May 18, advocates around the world will observe HIV Vaccine Awareness Day (HVAD)—an annual commemoration of the need for and commitment to the ongoing search for a vaccine. We invite you to join us on the day for a webinar—Vaccines in Vivo: Advances in AIDS Vaccine Research.
    May 5, 2015
    HIV Vaccine
    AVAC

  • Innovation and R&D in Post-2015 Development

    Where does R&D fit in the post-2015 development agenda that to date has stressed health, but not the research and implementation outcomes critical to making healthy lives a reality? The Global Health Technologies Coalition (GHTC), a group of more than 25 nonprofit organizations working to increase awareness of the urgent need for technologies that save lives in the developing world, has been hosting a series of webinars exploring the possibilities of innovation and access in the post-2015 sustainable development goals (SDGs).

    May 4, 2015
    General
    AVAC

  • Government Should Give Guidance on Drugs that Prevent HIV

    This piece by a 2014 AVAC Fellow marks the latest efforts by Ugandan civil society to secure pre-exposure prophylaxis (PrEP) access. Author Charles Brown is an advocate, based at the Infectious Diseases Institute (IDI), who spent the last year and a half advocating for PrEP rollout for groups at high-risk of HIV infection including young women, sex workers, men who have sex with men and serodiscordant couples in Uganda.

    May 2, 2015
    PrEP
    Charles Brown

Pages

view more